Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
| ▸ | STS | P08842 | 11/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22407314 | 0.81 | CA12 (0.47) | CA12CA14CA2EPHX1STS | |
| SCHEMBL22445488 | 0.79 | GPR119 (0.53) | CA12CA14CA2EPHX1STS | |
| SCHEMBL22441470 | 0.79 | GPR119 (0.53) | CA12CA14CA2EPHX1STS | |
| SCHEMBL23762384 | 0.79 | TGFBR1 (0.48) | CA12CA14CA2EPHX1HPGD | |
| SCHEMBL23726860 | 0.78 | HPGD (0.47) | CA12CA14CA2EPHX1STS | |
| SCHEMBL22441610 | 0.78 | CA12 (0.43) | CA12CA14CA2EPHX1STS | |
| SCHEMBL21970972 | 0.74 | HPGD (0.53) | EPHX1HPGDRECQLPTPN2PTPN1 | |
| SCHEMBL23726871 | 0.74 | EPHX1 (0.59) | CA12CA2EPHX1STSHPGD | |
| SCHEMBL22441472 | 0.73 | HPGD (0.55) | EPHX1HPGDRECQLPTPN2PTPN1 | |
| SCHEMBL24392527 | 0.72 | CA12 (0.48) | CA12CA14CA2EPHX1STS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3941459-B1 | QUINOLINE AND QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | STINGRAY THERAPEUTICS INC (US) | 2026-05-06 | — | — | EP | disclosed |
| US-11407729-B2 | Quinoline and quinazoline compounds and methods of use thereof | Stingray Therapeutics, Inc. (US) | 2022-08-09 | — | — | US | disclosed |
| US-11407729-B2 | Quinoline and quinazoline compounds and methods of use thereof | Stingray Therapeutics, Inc. (US) | 2022-08-09 | — | — | US | disclosed |
| EP-3941459-A1 | QUINOLINE AND QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | Stingray Therapeutics, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
| CN-113924092-A | Quinoline and quinazoline compounds and methods of use thereof | 斯汀格瑞治疗股份有限公司 | 2022-01-11 | — | — | CN | disclosed |
| US-20200299258-A1 | QUINOLINE AND QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | STINGRAY THERAPEUTICS INC (US) | 2020-09-24 | — | — | US | disclosed |
| US-20200299258-A1 | QUINOLINE AND QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | STINGRAY THERAPEUTICS INC (US) | 2020-09-24 | — | — | US | disclosed |
| WO-2020190912-A1 | QUINOLINE AND QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | Stingray Therapeutics, Inc. (US) | 2020-09-24 | — | — | WO | disclosed |
| WO-2020190912-A1 | QUINOLINE AND QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | Stingray Therapeutics, Inc. (US) | 2020-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200299258-A1 | QUINOLINE AND QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | ENPP1, ENPP3, PDE7A | CA12 4570/4885CA14 4194/4885CA2 3652/4885 |
| US-11407729-B2 | Quinoline and quinazoline compounds and methods of use thereof | ENPP1, ENPP3, PDE7A | CA12 4570/4885CA14 4194/4885CA2 3652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.